Biotech Values

[DewDiligence]

Re: Angiosyn Acquired by Pfizer

Good scoop by the WSJ to get this story a day early.

We don’t know now from the public disclosures how much of the $527M comes now vs later vs much later; however, this language:

“Full payment is contingent on successful completion of commercial development for an ophthalmic indication and a second therapeutic area.”

makes it sound like a big chunk of the money is much later.